Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment.

Addison PachecoSinead MaguireZoya QaiyumMichael TangAdam BridgerMelissa LimFataneh TavasolianEnoch YauSarah Q CromeNigil Haroon Robert Davies Inman

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2024)

The increased frequency of IL-17A-producing cells in SEC-NR patients suggests a larger inflammatory burden than SEC-R patients. With treatment, SEC-NR patients have a more pronounced type 1 IFN signature than SEC-R patients, suggesting a mechanism contributing to this larger inflammatory burden. The results point toward more immune heterogeneity in axSpA than has been recognized and highlights the need for precision therapeutics in this disease.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
oxidative stress
patient reported outcomes
ankylosing spondylitis
patient reported